The present invention relates to (1r, 1 ' R, 4R) -4- methoxyl groups -5 " bis- spiral shell [1,2 '-the 2 '-imidazoles of indenes -1 ' of hexamethylene -] -4 of-methyl -6 '-[5- (propyl- 1- alkynes -1- base) pyridin-3-yl] -3 ' H- "-amine camsilate,Pharmaceutical composition containing the salt and the salt treat the therapeutical uses of following A β-related pathologies with what: Down syndrome,Beta-amyloid protein angiosis for example but unlimited what Cerebral amyloid angiopathy or hereditary cerebral hemorrhage,Illness relevant to cognitive impairment for example but unlimited what MCI (" mild cognitive impairment "),Alzheimer disease,The loss of memory,The relevant attention deficit symptom of Ahl tribulus sea silent sickness,Neurodegeneration relevant to the disease of such as Alzheimer disease or it is dull-witted include mixed type blood vessel and denaturation source property dementia,Alzheimer's disease,Senile dementia,Dementia relevant to Parkinson's disease,Stein-leventhal syndrome or corticobasal degeneration.本發明涉及(1r,1’R,4R)-4-甲氧基-5”-甲基-6’-[5-(丙-1-炔-1-基)吡啶-3-基]-3’H-二螺[環己烷-1,2’-茚-1’2’-咪唑]-4”-胺的樟腦磺酸鹽，含有該鹽的藥物組合物和該鹽用於治療如下Aβ-相關病理的治療用途：唐氏綜合征、β-澱粉樣蛋白血管病例如但不限於腦澱粉樣蛋白血管病或遺傳性腦出血，與認知缺損相關的病症例如但不限於MCI(“輕度認知缺損”)、阿爾茨海默病、記憶喪失、與阿爾茨海默病相關的注意力缺陷症狀、與例如阿爾茨海默病的疾病相關的神經變性或痴呆包括混合型血管和變性源性痴呆、早老性痴呆、老年性痴呆、與帕金森病相關的痴呆、進行性核上性麻痹或皮質基質變性。
